Buy Rating on Seres Therapeutics Backed by Strong SER-155 Study Progress and Potential in Transplant Health

John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on Seres Therapeutics (MCRB – Research Report). The associated price target remains the same with $15.00.

John Newman has given his Buy rating due to a combination of factors related to the anticipated performance of Seres Therapeutics’ product, SER-155. Newman highlights the importance of the microbiome in transplant health and the product’s potential to reduce complications such as bloodstream infections and Graft versus Host Disease. He notes that SER-155 is designed to lower pathogen domination and febrile neutropenia, which could be critical in improving transplant outcomes. Furthermore, Newman emphasizes the successful enrollment and randomization of patients in cohort 2 of the Phase 1b study, which is a significant step toward validating SER-155’s efficacy.
Additionally, Newman’s positive outlook is bolstered by the preliminary data from cohort 1 of the Phase 1b study, which demonstrated a significant reduction in harmful pathogen domination when compared to historical benchmarks. This suggests a promising outlook for the ongoing cohort 2 study results. Newman also points out that infection and Graft versus Host Disease are leading causes of mortality post-stem cell transplant, and SER-155 targets these key issues. Moreover, the ease of integrating SER-155 into existing transplant protocols could facilitate its adoption in clinical settings. With these considerations, Newman maintains a Buy rating and sets a price target for Seres Therapeutics’ stock, reflecting optimism for the company’s revenue growth and the potential success of SER-155.

In another report released on May 9, Chardan Capital also maintained a Buy rating on the stock with a $6.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Seres Therapeutics (MCRB) Company Description:

Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the development of biological drugs. The firm creates medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. Berry and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.